Cardiovascular Health

The endothelial glycocalyx is the gel-like protective lining of every blood vessel in your body. It degrades with age, chronic inflammation, high blood sugar, and oxidative stress — and once damaged, it allows LDL and inflammatory particles direct access to the arterial wall, initiating plaque. Arterosil HP delivers rhamnan sulfate from the rare seagrass Monostroma nitidum — the only compound in peer-reviewed literature demonstrated to support glycocalyx restoration. In a 6-month case series of 6 high-risk patients, average carotid plaque area was reduced by 5.55mm² as confirmed by ultrasound imaging. The mechanism is upstream of almost everything else in cardiovascular supplementation: you can take all the omega-3 and CoQ10 in the world, but if your vascular lining is compromised, the protection is limited. This is why it ranks #1 here.

Nitric oxide (NO) is the master vasodilator of the cardiovascular system — it signals blood vessels to relax, reduces platelet aggregation, and is anti-inflammatory at the endothelial level. NO production declines 50% or more between age 40 and 70. Vascanox HP goes further than standard beet-based NO supplements by also supporting hydrogen sulfide (H₂S), a separate gasotransmitter with independent vasoprotective and anti-aging effects at the cellular level. An open-label human study confirmed significant NO elevation with Vascanox HP. Used clinically as a pair with Arterosil HP: Arterosil restores the glycocalyx structure; Vascanox optimizes the vascular signaling environment within it. The combination addresses both the architecture and the biochemistry of arterial health simultaneously.

The REDUCE-IT trial (8,179 patients, NEJM 2018) showed 25% relative risk reduction in major cardiovascular events. The EVAPORATE trial confirmed coronary plaque regression at 18 months — the only supplement with imaging-confirmed plaque reduction in an RCT. Mechanism: anti-inflammatory, anti-thrombotic, membrane-stabilizing. This is the gold standard of cardiovascular supplement evidence.

The Q-SYMBIO trial (420 patients, JACC Heart Failure 2014) showed CoQ10 300mg/day halved all-cause mortality in chronic heart failure over 2 years — the first supplement to improve hard outcomes in heart failure in over a decade. Essential for statin users (statins deplete CoQ10). Ubiquinol form (reduced CoQ10) shows 3–8× superior absorption vs. standard ubiquinone, especially in patients over 50.

Triglyceride-form omega-3 provides significantly higher bioavailability than ethyl ester forms. 138+ RCTs confirm benefits for triglycerides (25–50% reduction at 2–4g/day EPA+DHA), endothelial function, inflammation, and arrhythmia. Best OTC alternative to prescription Vascepa. Key: dose and purity matter — look for high-concentration TG-form products with 3rd-party testing.

Galectin-3 is a lectin protein produced in excess by damaged or senescent cells — it drives organ fibrosis, chronic inflammation, and cancer cell proliferation. Elevated galectin-3 is an independent predictor of cardiovascular mortality and heart failure progression, with FDA-cleared diagnostic tests (CardioSave) now measuring it routinely. PectaSol-C is the only clinically studied galectin-3 inhibitor derived from modified citrus pectin. Its evidence base spans 100+ published studies including human RCTs: a Phase II RCT (Keizman et al., Nutrients 2021/2023) showed disease stabilization in biochemically recurrent prostate cancer; additional human trials confirm galectin-3 reduction, heavy metal chelation, and kidney protection in chronic kidney disease. Cardiovascular relevance: galectin-3 drives cardiac fibrosis and myocardial stiffness — inhibiting it preserves diastolic function and reduces fibrotic remodeling post-myocardial injury. Best-in-class for its mechanism; no other commercial product offers clinical-grade galectin-3 inhibition.

A 20-herb Tibetan botanical formula with over 60 years of published research and 30+ clinical trials — more human data than most single-ingredient cardiovascular supplements. A 2024 meta-analysis of 19 trials (2,084 patients, published in Atherosclerosis) confirmed significant efficacy for peripheral arterial disease (PAD), improving maximum walking distance vs. placebo (p<0.001). A Cochrane review of 5 RCTs (365 participants) independently confirmed the PAD/intermittent claudication evidence. Anti-inflammatory (inhibits AGE formation ~58%), anti-oxidative (inhibits AOPP ~79%), and antiplatelet mechanisms validated across decades of study. Uniquely, Padma 28 is registered as a pharmaceutical drug in Switzerland — one of the few botanical formulas to achieve that regulatory threshold. Tier B because most trials focus on PAD/intermittent claudication rather than broader cardiovascular endpoints; larger trials in general CV populations are needed.

The nattokinase evidence base is among the most compelling in cardiovascular supplementation. A 2022 clinical study of 1,062 patients (Frontiers in Cardiovascular Medicine) showed 10,800 FU/day nattokinase reduced carotid artery plaque by 36% and significantly lowered LDL cholesterol and triglycerides over 12 months. A meta-analysis of multiple RCTs confirms significant systolic and diastolic blood pressure reduction (−3.45 mmHg and −2.32 mmHg respectively). 17 total human studies support fibrinolytic activity. Toku Flow combines this with K2 MK-7 (arterial decalcification — Rotterdam Study, reduced cardiovascular mortality 57%) and beta-glucan (LDL reduction confirmed in multiple RCTs). It is the only single formulation stacking all three mechanisms: fibrinolysis, arterial decalcification, and LDL reduction. Recommended dose: 10,800 FU daily — exactly the dose used in the Chen et al. 2022 study that demonstrated 36% plaque reduction. This is the research-validated protocol dose.

Neo40 delivers nitric oxide through direct sublingual lozenge dissolution — a distinct mechanism from dietary beet nitrates. A blinded placebo-controlled crossover RCT (n=30 hypertensive patients, Journal of Clinical Hypertension) demonstrated acute systolic blood pressure reduction, improved vascular compliance, and restored endothelial function from a single dose. A separate 30-day randomized double-blind placebo-controlled trial (n=29) confirmed sustained BP reduction plus a 55-meter improvement in the 6-minute walk test — a validated functional cardiovascular endpoint. Formula licensed from the University of Texas Health Science Center. Collaboration studies with Cedars-Sinai and Vanderbilt. Mechanistic foundation: Nobel Prize-winning nitric oxide biology (Furchgott, Ignarro, Murad, 1998). COI note: Both trials were industry-funded by HumanN/Neogenis Labs — independent replication not yet completed.

Dietary nitrates from beets convert to nitric oxide via the salivary nitrate-nitrite pathway. A randomized crossover study showed significant blood pressure reduction after 4 weeks of beet-derived nitrate supplementation. SuperBeets Heart Chews combine concentrated beet nitrates with grape seed extract (OPCs). Best evidence-accessible consumer product for NO support at an approachable price point.

Magnesium is required for over 300 enzymatic reactions including ATP synthesis, vascular smooth muscle relaxation, and electrical conduction in the heart. Deficiency is associated with arrhythmia, hypertension, and increased cardiovascular mortality. Meta-analyses confirm modest but consistent blood pressure reductions (avg 3–4 mmHg systolic). Glycinate/bisglycinate forms have superior absorption and lowest GI side effect profile.

Vitamin K2 (MK-7 form) activates Matrix Gla Protein (MGP), which inhibits arterial calcification. The Rotterdam Study showed that the highest K2 intake quartile had 52% lower cardiovascular mortality. K2 deficiency allows calcium to deposit in arterial walls rather than bones. D3 and K2 work synergistically — D3 increases calcium absorption, K2 directs it to bone. Critical pairing for arterial stiffness prevention.

Plant sterols structurally resemble cholesterol and competitively inhibit intestinal cholesterol absorption. Meta-analyses of 84 RCTs show consistent LDL-C reduction of 8–10% at 2g/day — without the side effects of statins. Endorsed by the American Heart Association for adjunct cholesterol management. Best evidence-to-safety ratio of any LDL-lowering supplement.